Stock Price Quote

LYKA LABS LTD.

NSE : LYKALABSBSE : 500259ISIN CODE : INE933A01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE128.500.7 (+0.55 %)
PREV CLOSE ( ) 127.80
OPEN PRICE ( ) 128.75
BID PRICE (QTY) 128.75 (44)
OFFER PRICE (QTY) 129.25 (30)
VOLUME 581
TODAY'S LOW / HIGH ( )128.50 129.60
52 WK LOW / HIGH ( )89 143.5
NSE129.000.8 (+0.62 %)
PREV CLOSE( ) 128.20
OPEN PRICE ( ) 129.95
BID PRICE (QTY) 128.95 (120)
OFFER PRICE (QTY) 129.45 (157)
VOLUME 7015
TODAY'S LOW / HIGH( ) 127.85 129.95
52 WK LOW / HIGH ( )88.5 144.3
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 29-12 1976
Management Info
Babulal Jain - Chairman Kunal N Gandhi - Managing Director
Registered Office

Address 4801/B & 4802/A,G I D C Industrial Estate, ,
Ankleshwar,
Gujarat-393002

Phone 02646221422 /220549

Email companysecretary@lykalabs.com

Website www.lykalabs.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,L B S Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

19Apr Update On The Scheme Of Amalgamation
Update on the Scheme of Amalgamation w.r.t its next hearing is enclosed..
18Apr Lyka Labs informs about disclosure
Lyka Labs has informed that it enclosed disclosure under Regulation 29(2..
08Apr Allotment of Equity Shares
Inter alia, to consider and approve :- (1) to allot and issue 2600000..
16Jan Lyka Labs informs about change in dire
Lyka Labs has informed that the Board of Directors has approved appointm..
03Jan Lyka Labs informs about loss of share
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclo..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit13.64-132.86
Gross Profit 24.01 -132.08
Operating Profit 63.77190.52
Net Sales 314.15805.93

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2719.00 (3.74%)
M.Cap ( in Cr)1619.26
Vimta Labs (BSE)
peergroup  568.00 (11.49%)
M.Cap ( in Cr)1129.48
Bharat Parenterals (BSE)
peergroup  1599.00 (3.35%)
M.Cap ( in Cr)900.36
Astrazeneca Pharma I (BSE)
peergroup  5304.10 (0.66%)
M.Cap ( in Cr)13173.25
Natco Pharma (BSE)
peergroup  1032.90 (3.35%)
M.Cap ( in Cr)17901.14

Shareholding Pattern

PROMOTERS 54.81%
NON-INSTITUTION 44.21%
FI/BANKS/INSURANCE 0.4%
MUTUAL FUNDS/UTI 0.01%
GOVERNMENT 0%
FII 0%

About Lyka Labs Ltd.

Lyka Labs Ltd. was incorporated in the year 1976. Its today's share price is 128.5. Its current market capitalisation stands at Rs 422.89 Cr. In the latest quarter, company has reported Gross Sales of Rs. 805.93 Cr and Total Income of Rs.840.44 Cr. The company's management includes Kishore P Shah, Yogesh Shah, Shashil P Mendonsa, Kunal N Gandhi, Dhara Shah, Prashant Godha, Babulal Jain.

It is listed on the BSE with a BSE Code of 500259 , NSE with an NSE Symbol of LYKALABS and ISIN of INE933A01014. It's Registered office is at 4801/B & 4802/A,G I D C Industrial Estate, Ankleshwar-393002, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are D Kothary & Co, MA Parikh & Co, Mehta Chokshi & Shah

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.